Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
uniQure Investors With Significant Losses Are Encouraged To Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson To Discuss Their Legal Rights
QURE Stock Crashes 32% in a Week: Here's What You Should Know
11:01am, Friday, 06'th Mar 2026
uniQure stock plunges 32% in a week after the FDA says AMT-130 phase I/II Huntington's disease data are not sufficient as primary evidence for a potential marketing application.
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
10:45am, Friday, 06'th Mar 2026
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
10:30am, Friday, 06'th Mar 2026
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. (“uniQure” or
New York, New York--(Newsfile Corp. - March 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24
Federal health officials, facing criticism from lawmakers for recent rejections of rare-disease drugs, attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment
NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).
Holzer & Holzer, LLC Reminds QURE Investors of the April 13, 2026 Lead Plaintiff Deadline in the uniQure N.V. Securities Class Action
03:54pm, Thursday, 05'th Mar 2026
ATLANTA, March 05, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The lawsuit alleges that Defenda
FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease
02:42pm, Thursday, 05'th Mar 2026
UniQure needs to run another study to prove its gene therapy "actually helps people with Huntington's disease," a senior FDA official said. The official said UniQure is the "latest company to make a f
Sr. FDA official calls Uniqure's Huntington's disease treatment a failure
01:11pm, Thursday, 05'th Mar 2026
A senior FDA official called Uniqure's experimental Huntington's disease treatment a "failed product" in a conference call with media members on Thursday, casting furt
FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial
12:11pm, Thursday, 05'th Mar 2026
An official from the U.S. Food and Drug Administration (FDA) defended the agency's request for a new placebo-controlled study for uniQure N.V.'s (NASDAQ: QURE) experimental gene therapy for Huntington
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Thursday, 05'th Mar 2026
New class action for uniQure N.V. (QURE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/13/2026.
QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
08:57am, Thursday, 05'th Mar 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V.
08:27am, Thursday, 05'th Mar 2026
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
04:39am, Thursday, 05'th Mar 2026
LOS ANGELES, March 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) a
